Literature DB >> 671224

A model for the prospective identification of the prenephrotoxic state during gentamicin therapy.

W A Colburn, J J Schentag, W J Jusko, M Gibaldi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 671224     DOI： 10.1007/BF01312260

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN： 0090-466X


× No keyword cloud information.
  9 in total

1.  Pharmacokinetic analysis of drug concentration data obtained during repetitive drug administration.

Authors:  W A Colburn; D Shen; M Gibaldi
Journal:  J Pharmacokinet Biopharm       Date:  1976-12

2.  Renal clearance and tissue accumulation of gentamicin.

Authors:  J J Schentag; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1977-09       Impact factor: 6.875

3.  Gentamicin: toxicity in perspective.

Authors:  W L Hewitt
Journal:  Postgrad Med J       Date:  1974-11       Impact factor: 2.401

4.  Correlation of serum creatinine concentration and gentamicin half-life.

Authors:  R E Cutler; A M Gyselynck; W P Fleet; A W Forrey
Journal:  JAMA       Date:  1972-02-21       Impact factor: 56.272

5.  Some considerations as to the determination and significance of biologic half-life.

Authors:  M Gibaldi; H Weintraub
Journal:  J Pharm Sci       Date:  1971-04       Impact factor: 3.534

6.  Pharmacokinetic analysis of drug concentration data obtained during repetitive drug administration.

Authors:  W A Colburn; M Gibaldi
Journal:  J Pharm Sci       Date:  1977-04       Impact factor: 3.534

7.  Gentamicin therapy in renal failure: a nomogram for dosage.

Authors:  R A Chan; E J Benner; P D Hoeprich
Journal:  Ann Intern Med       Date:  1972-05       Impact factor: 25.391

8.  Gentamicin dosages for renal insufficiency. Adjustments based on endogenous creatinine clearance and serum creatinine concentration.

Authors:  M C McHenry; T L Gavan; R W Gifford; N A Geurkink; R A Van Ommen; M A Town; J G Wagner
Journal:  Ann Intern Med       Date:  1971-02       Impact factor: 25.391

9.  Gentamicin disposition and tissue accumulation on multiple dosing.

Authors:  J J Schentag; W J Jusko; J W Vance; T J Cumbo; E Abrutyn; M DeLattre; L M Gerbracht
Journal:  J Pharmacokinet Biopharm       Date:  1977-12
  9 in total
  5 in total

1.  Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man.

Authors:  S M Carlsson; T Denneberg; B M Emanuelsson; B Kågedal; S Lindgren
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of aminoglycoside antibiotics.

Authors:  J C Pechere; R Dugal
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

3.  D-Propoxyphene: accumulation or altered kinetics?

Authors:  W A Colburn; C E Inturrisi
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  A model for dosing gentamicin in children and adolescents that adjusts for tissue accumulation with continuous dosing.

Authors:  W E Evans; R H Taylor; S Feldman; W R Crom; G Rivera; G C Yee
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

Review 5.  Cost considerations in therapeutic drug monitoring of aminoglycosides.

Authors:  J S Bertino; K A Rodvold; C J Destache
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.